TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+6.54%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$513M
AUM Growth
+$513M
(-9.5%)
Cap. Flow
-$40.9M
Cap. Flow
% of AUM
-7.98%
Top 10 Holdings %
Top 10 Hldgs %
77.97%
Holding
24
New
3
Increased
3
Reduced
5
Closed
2
Top Buys
| 1 |
Dyne Therapeutics
DYN
|
$19M |
| 2 |
Structure Therapeutics
GPCR
|
$8.33M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$6.64M |
| 4 |
Geron
GERN
|
$5.59M |
| 5 |
C4 Therapeutics
CCCC
|
$3.93M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$33.5M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$24.9M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$10.5M |
| 4 |
Viridian Therapeutics
VRDN
|
$8.14M |
| 5 |
Aclaris Therapeutics
ACRS
|
$4.98M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $125M | 24.38% | 5,141,118 | – | – |
|
2
Cogent Biosciences
COGT
$1.69B
| $39.2M | 7.64% | 3,631,042 | – | – |
|
|
3
Geron
GERN
$893M
| $38.6M | 7.51% | 17,765,213 +2,578,140 | +17% | +$5.59M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $36.3M | 7.08% | 149,917 -138,137 | -48% | -$33.5M |
|
5
Tyra Biosciences
TYRA
$675M
| $32M | 6.23% | 1,989,103 | – | – |
|
6
Ventyx Biosciences
VTYX
$171M
| $27.3M | 5.33% | 815,724 +28,493 | +4% | +$955K |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $26.7M | 5.2% | 3,395,495 | – | – |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $26.6M | 5.18% | 3,048,257 -2,857,143 | -48% | -$24.9M |
|
|
VECT
9
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $26.5M | 5.16% | 3,113,600 +780,300 | +33% | +$6.64M |
|
|
JBIO
10
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $21.8M | 4.25% | 1,081,274 | – | – |
|
|
11
Dyne Therapeutics
DYN
$1.92B
| $19M | 3.71% | +1,650,150 | New | +$19M |
|
12
Kura Oncology
KURA
$686M
| $17.4M | 3.39% | 1,423,642 | – | – |
|
|
13
Viridian Therapeutics
VRDN
$1.5B
| $16.9M | 3.29% | 663,610 -320,000 | -33% | -$8.14M |
|
|
SLN
14
Silence Therapeutics
SLN
$227M
| $13.1M | 2.54% | 2,104,875 | – | – |
|
15
Immunovant
IMVT
$2.56B
| $10.2M | 1.98% | 654,853 -200,000 | -23% | -$3.1M |
|
16
Entrada Therapeutics
TRDA
$208M
| $8.48M | 1.65% | 584,955 | – | – |
|
|
17
Structure Therapeutics
GPCR
$1.11B
| $8.33M | 1.62% | +350,000 | New | +$8.33M |
|
18
Merus
MRUS
$4.98B
| $5.52M | 1.08% | 300,000 | – | – |
|
|
19
Aclaris Therapeutics
ACRS
$209M
| $4.29M | 0.84% | 529,839 -615,100 | -54% | -$4.98M |
|
20
Cabaletta Bio
CABA
$133M
| $4.03M | 0.78% | 486,795 | – | – |
|
|
21
C4 Therapeutics
CCCC
$185M
| $3.93M | 0.77% | +1,250,000 | New | +$3.93M |
|
|
ALPN
22
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $1.95M | 0.38% | 253,069 | – | – |
|
|
ELEV
23
DELISTED
Elevation Oncology
ELEV
| – | – | -288,390 | Closed | -$274K |
|
|
24
MoonLake Immunotherapeutics
MLTX
$3.54B
| – | – | -1,000,000 | Closed | -$10.5M |
|